The role of rare copy number variants in depression

Dr Kimberley M Kendall¹, Dr Elliott Rees¹, Matthew Bracher-Smith¹, Dr Lucy Riglin¹, Prof Stanley Zammit^{1,2}, Prof Michael C O'Donovan¹, Prof Michael J Owen¹, Prof Ian Jones¹, Prof George Kirov¹, Dr James T R Walters¹

1. MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University
2. Centre for Academic Mental Health, Department of Population Health Sciences, University of Bristol

Corresponding author:

Dr James Walters

MRC Centre for Neuropsychiatric Genetics and Genomics, Division of Psychological Medicine and Clinical Neurosciences, Cardiff University

Hadyn Ellis Building

Maindy Road

Cardiff

CF24 4HQ

02920 688434

waltersjt@cardiff.ac.uk

Abstract

The role of large, rare copy number variants (CNVs) in neurodevelopmental disorders is well-established,¹⁻⁵ but their contribution to common psychiatric disorders, such as depression, remains unclear. We have previously shown that a substantial proportion of CNV enrichment in schizophrenia is explained by CNVs associated with neurodevelopmental disorders.^{6,7} Depression shares genetic risk with schizophrenia^{8,9} and is frequently comorbid with neurodevelopmental disorders^{10,11}, suggesting to us the hypothesis that if CNVs play a role in depression, neurodevelopmental CNVs are those most likely to be associated. We confirmed this in UK Biobank by showing that neurodevelopmental CNVs were associated with depression (24,575 cases, 5.87%; OR=1.36, 95% CI 1.22–1.51, $p=1.61 \times 10^{-8}$), whilst finding no evidence implicating other CNVs. Four individual neurodevelopmental CNVs increased risk of depression (1q21.1 duplication, PWS duplication, 16p13.11 deletion, 16p11.2 duplication). The association between neurodevelopmental CNVs and depression was partially explained by social deprivation but not by education attainment or physical illness.

Studies of CNVs in depression have been based on relatively small samples¹²⁻¹⁸, have generated inconsistent results, and no findings have met criteria for genome-wide significance. The UK Biobank offers an opportunity to investigate the relationship between CNVs and depression on a larger-scale than has hitherto been possible. We performed a CNV analysis of depression in UK Biobank data of 455,913 individuals who reported white British or Irish ethnicity (Methods). Our primary definition of depression was participant self-report of ever having received a medical diagnosis of depression ('self-reported depression'). To ensure our findings were not restricted to this definition, we also tested two more conservative phenotypes – (i) self-reported depression with an additional requirement for antidepressant prescription, and (ii) a hospital discharge diagnosis of depression. We sought association with depression for (i) a group of 53 CNVs known to be associated with neurodevelopmental disorders ('neurodevelopmental CNVs')^{6,7} and (ii) after excluding CNVs relevant to the primary hypothesis, we tested for a residual unexplained burden among CNVs $\geq 100\text{KB}$, $\geq 500\text{KB}$ and $\geq 1\text{MB}$.

24,575 individuals (5.87%) had self-reported depression and 394,205 individuals reported no lifetime depression (Figure 1). The group of 53 neurodevelopmental CNVs was associated with depression in our primary analysis (OR=1.36, 95% CI 1.22 – 1.51, uncorrected $p=1.61 \times 10^{-8}$). Of individuals with depression 1.54% ($n = 379$) carried at least one of the 53 neurodevelopmental CNVs compared with 1.14% ($n = 4,510$) of controls. Analysis of the alternative depression phenotypes produced consistent results (Table 1), with the effect size increasing with more conservative definitions of

depression. The association between the neurodevelopmental CNVs and self-reported depression remained after removing cases with a hospital discharge diagnosis of depression (OR=1.37, 95% CI 1.23 – 1.52, uncorrected $p=6.27 \times 10^{-9}$). Restricting these analyses to the subset of schizophrenia-associated CNVs generated similar results.

After exclusion of the 53 neurodevelopmental CNVs, there was a weak association between CNVs $\geq 500\text{KB}$ and depression, which did not survive correction for multiple testing. There was no evidence for association between CNVs $\geq 100\text{KB}$, $\geq 1\text{MB}$ and depression (Table 1).

Exploratory analyses of individual neurodevelopmental CNVs found 10 CNVs to be nominally associated with self-reported depression, of which four (1q21.1 duplication, Prader Willi syndrome duplication, 16p13.11 deletion and 16p11.2 duplication) survived Bonferroni correction for the 53 CNVs tested (p value threshold 0.00094, Figure 2, Supplementary Table 1).

The addition of genotyping platform as a covariate in regression analyses did not change the results as presented.

We used data from 157,397 individuals who completed an online follow-up mental health questionnaire to examine association between CNVs and markers of depression severity (age at onset, number of episodes of depression, duration of worst depressive episode). We restricted these analyses to the 73,234 individuals who reported experience of prolonged feelings of sadness or

depression (61,467 unaffected), a phenotype which itself was associated with neurodevelopmental CNV carrier status (OR=1.19, 95% 1.06-1.33, $p=0.004$). We did not find any association between neurodevelopmental CNVs and markers of depression severity that survived correction for multiple testing (Supplementary Table 2).

In order to better understand the relationship between neurodevelopmental CNVs and depression, we investigated whether the association was explained by measures of (i) educational attainment (qualifications), (ii) physical health (number of non-psychiatric hospital admission diagnoses) and (iii) social deprivation (Townsend Deprivation Index). These variables were chosen because of their known associations with depression^{19,20}, their postulated or proven association with CNVs and their availability in a large proportion of the UK Biobank (UKBB) sample. The association between neurodevelopmental CNVs and depression was partially explained by social deprivation (Figure 3, Supplementary Tables 3a, 3b) but not by level of education or physical health. There remained a strong independent association between these CNVs and depression in analyses incorporating these other measures.

Given recent evidence for an increased rate of large CNVs in female children with anxiety or depression²¹, we undertook exploratory analyses which provided weak evidence for a higher rate of depression in female neurodevelopmental CNV carriers than males. This increased rate was over and above the baseline increased rate of self-reported depression in females (interaction term OR=0.78, 95% CI 0.62 – 0.98, uncorrected $p=0.03$, Supplementary Table 4) although this

effect was weaker still and non-significant for our secondary depression definitions.

Here we report the largest study of CNVs in depression to date. We tested two main hypotheses – (i) that risk CNVs for neurodevelopmental disorders would be associated with depression and, (ii) that, after excluding CNVs relevant to the primary hypothesis, there would be a residual unexplained burden among CNVs $\geq 100\text{KB}$, $\geq 500\text{KB}$ and $\geq 1\text{MB}$. Our results support our first hypothesis – CNVs previously associated with neurodevelopmental disorders were associated with increased risk of lifetime depression, whether defined on the basis of self-reported diagnosis, this combined with antidepressant treatment or on hospital discharge diagnosis. Four neurodevelopmental CNVs (1q21.1 duplication, PWS duplication, 16p13.11 deletion, 16p11.2 duplication) were individually associated with depression at levels of significance that survived Bonferroni correction for the 53 CNVs tested. We note that none of these CNV loci overlap with risk loci recently identified in a large depression genome-wide association study⁹. The risk of depression in CNV carriers in this study (whether CNVs are considered individually or collectively) was lower than that identified in previous studies of schizophrenia but qualitatively, the results followed a similar pattern - the highest risk for both disorders was conferred by 3q29del (depression OR=10.72, schizophrenia OR =57.65) and the lowest risk for both disorders was conferred by 16p12.1del (depression OR=1.59, schizophrenia OR=3.3).^{5,6} After excluding neurodevelopmental CNVs we found no evidence of residual burden of risk for depression among CNVs $\geq 100\text{KB}$, $\geq 500\text{KB}$ and $\geq 1\text{MB}$.

Further investigation of the association between neurodevelopmental CNVs and depression indicated that this relationship is partially explained by social deprivation. To our knowledge this is the first report showing these CNVs are associated with neighbourhood measures of social deprivation, and thus implicates an important mechanism by which CNV carrier status could increase risk of depression, although longitudinal data on these measures is needed to establish the causal directionality between depression and social deprivation.

We acknowledge some limitations of this study. Our primary depression definition relied on self-report, a method known to be subject to information bias.²² However, this is unlikely to have markedly influenced our findings given the almost identical, or even stronger, results from using the clinicians' hospital discharge diagnosis of depression phenotype. Another limitation is the relatively low rate of depression compared to population estimates²³. While this likely reflects the better than average health and functioning of the UK Biobank sample, and imprecision in the definition of disorder, these factors are not likely to have generated spurious CNV associations.

Neurodevelopmental CNVs have incomplete penetrance for major developmental disorders²⁴, yet beyond mild cognitive impairment^{25,26}, little is known about phenotypic associations with CNV carrier status. Our study is the first to robustly demonstrate association between these CNVs and depression and thus extends the spectrum of clinical phenotypes that are associated with CNV carrier status.

Methods

Sample

Between 2006 and 2010, UK Biobank recruited ~500,000 individuals (54% female) aged 37 – 73 years living in the United Kingdom. Ethical approval was granted to UK Biobank by the North West Multi-Centre Ethics Committee and all participants provided informed consent to participate in UK Biobank projects. Phenotypic data were collected at assessment centres via touchscreen devices and nurse-led interviews. Participants provided blood, urine and saliva samples. This study was conducted under the conditions of UK Biobank project number 14421.

Depression Phenotypes

Analyses of depression in the UK Biobank to date have used multiple definitions of the disorder.^{27,28} In view of this lack of consensus regarding case definition, we began by using a relatively liberal definition of lifetime depression, rating as cases those individuals who reported a doctor had told them they have depression (self-reported depression code 1286, UKBB field 20002. We repeated our analyses using two alternative, more conservative definitions of depression – lifetime self-reported depression with current antidepressant prescription at the time of visit 1 and, hospital discharge diagnosis of depression. *Self-reported depression with antidepressant prescription at visit 1* - we constructed a binary depression variable using (i) the self-reported depression code 1286 in UKBB field 20002 and (ii) antidepressant prescription codes in UKBB field 20003. Individuals were included as affected if they reported that a doctor had told them they have depression and they were prescribed an antidepressant

medication at the time of first assessment. Individuals, who fulfilled only one of the two criteria i.e. self-reported depression or antidepressant prescription alone, were excluded from analyses. *Hospital discharge diagnosis of depression* – individuals were included as affected if they had a hospital admission with a primary or secondary ICD-10 code for depression (UKBB fields 41202 and 41204) (Figure 1). For individuals assessed at Scottish assessment centres, hospital records covered general hospitals but not psychiatric hospitals (for Wales and England these covered both). For these individuals, we accepted a secondary ICD-10 code for depression as evidence of depression diagnosis as this could be coded during admission to a general hospital. However, in the absence of primary ICD-10 codes for depression, we were unable to determine the absence of depression in controls. Therefore, we removed Scottish controls from this variable.

In 2017, 157,397 individuals completed an online follow-up mental health questionnaire. We aimed to further characterise associations with depression phenotypes in individuals who stated that they had ever experienced prolonged feelings of sadness or depression on this questionnaire (UKBB field 20446). We examined data from the following variables - (i) age at first episode of depression (UKBB field 20433), (ii) duration of worst depression (UKBB field 20438) and (iii) lifetime number of depressed episodes (UKBB field 20442). *Duration of worst depression (UKBB field 20438)* – this was coded in ranges of months e.g. less than a month, between one month and three months. Previous data has shown that the median duration of a depressive episode is 3 months.²⁹ Therefore, this variable was dichotomised into 0-3 months and more than 3

months. *Lifetime number of depressed episodes (UKBB field 20442)* – this variable was dichotomised using a median split approach (median = 1).

Genotyping and CNV Calling

DNA was extracted from whole blood³⁰ and then genotyped at the Affymetrix Research Services Laboratory, Santa Clara, CA on the UK Biobank Axiom and UK BiLEVE arrays. Genotypes were released to Cardiff University after application to UK Biobank (project number 14421). CNV calling was carried out using PennCNV-Affy³¹ using biallelic markers common to both genotyping platforms and is described in detail elsewhere.²⁵ CNV burden analysis was carried out on the CNV calls generated by Penn-CNV-Affy using PLINK 1.07.³² Individual samples were excluded if they had ≥ 30 CNVs, a waviness factor of >0.03 or <-0.03 , a SNP call rate of $<96\%$ or LRR SD of >0.35 . Individual CNVs were excluded if they were covered by <20 probes, had a density coverage of <1 probe per 20,000 base pairs or a confidence score of <10 .

Defining Copy Number Variant Sets and Analysis

Following the approach of our recent study using UK Biobank data²⁵ we defined a group of ‘neurodevelopmental CNVs’ as those 54 CNVs for which there is at least nominally significant evidence for association with neurodevelopmental disorders ($p < 0.05$).³ We excluded the high frequency 15q11.2 duplication resulting in a final list of 53 ‘neurodevelopmental CNVs’. In exploratory analyses each of the CNVs for which there were ≥ 5 observations were analysed individually for association with self-reported depression.

CNV burden analyses were carried out using PLINK on regions of variable copy number at three size thresholds: (i) $\geq 100\text{KB}$, (ii) $\geq 500\text{KB}$ and (iii) $\geq 1\text{MB}$. CNVs were filtered for frequency at $<1\%$ using the `--cnv-freq-exclude-above` command and overlapping lower copy repeat regions were filtered out using the `--cnv-exclude` command. PLINK outputs were converted into CNV carrier status, which was used as the outcome in regression analyses. For all burden analyses, the group of 53 CNVs associated with neurodevelopmental disorders were excluded.

Association analyses were carried out in R using logistic or linear regression as appropriate with age and sex as covariates. Analyses were restricted to those who reported white British or Irish ethnicity and we excluded individuals with CNV-associated neurodevelopmental/neuropsychiatric disorders (autism spectrum disorder (ASD), intellectual disability (ID), attention deficit hyperactivity disorder (ADHD), schizophrenia or bipolar affective disorder (BPAD)) from being cases and controls.

Further Investigation of the Neurodevelopmental CNV-Depression

Association

In order to better understand the association between neurodevelopmental CNVs and depression we investigated whether the association was explained by three variables known to be associated with depression^{19,20} and postulated to be associated with CNVs – (i) educational attainment (qualifications), (ii) physical health (number of non-psychiatric hospital admission diagnoses) and, (iii) social deprivation (Townsend Deprivation Index). *Educational attainment*: Prior to analysis, data from the academic qualifications field were dichotomised and

recoded into college/university degree or all other qualifications, an approach previously used for this data field (UKBB field 6138).³³ *Physical health*: We used number of hospital admission physical health codes as a proxy measure of the extent of physical health problems (excluding psychiatric codes; UKBB fields 41202 and 41204). *Social deprivation*: This was measured using Townsend Deprivation Index codes (UKBB field 189). Analyses were carried out using structural equation modelling in the lavaan package in R.³⁴ The proportion explained was estimated by indirect effect/total effect. Age and sex were used as covariates throughout the analyses.

Sex-Specific Analyses

Previous studies have reported a small but significant excess of large ($\geq 500\text{KB}$) rare ($< 1\%$) CNVs in females.³⁵ Recent evidence has also suggested that female children with anxiety or depression are more likely to carry large CNVs than males.²¹ This led us to examine rates of depression in female and male CNV carriers in our sample. Following finding that there was an excess of female CNV carriers with depression, we added an interaction term consisting of the product of neurodevelopmental CNVs and sex, to our main regression model.

Acknowledgements

This work was funded by a Wellcome Trust Clinical Research Training Fellowship awarded to K Kendall. The work at Cardiff University was supported by Medical Research Council (MRC) Centre (MR/L010305/1), Program (G0800509) and Project (MR/L011794/1) grants.

References

1. Cooper, G.M. *et al.* A copy number variation morbidity map of developmental delay. *Nat Genet* **43**, 838-46 (2011).
2. Williams, N.M. *et al.* Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: the role of rare variants and duplications at 15q13.3. *Am J Psychiatry* **169**, 195-204 (2012).
3. Coe, B.P. *et al.* Refining analyses of copy number variation identifies specific genes associated with developmental delay. *Nat Genet* **46**, 1063-71 (2014).
4. Girirajan, S. *et al.* Relative burden of large CNVs on a range of neurodevelopmental phenotypes. *PLoS Genet* **7**, e1002334 (2011).
5. Rees, E. *et al.* Analysis of copy number variations at 15 schizophrenia-associated loci. *Br J Psychiatry* **204**, 108-14 (2014).
6. Rees, E. *et al.* Analysis of Intellectual Disability Copy Number Variants for Association With Schizophrenia. *JAMA Psychiatry* **73**, 963-9 (2016).
7. Rees, E. *et al.* CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. *Hum Mol Genet* **23**, 1669-76 (2014).
8. Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* **381**, 1371-9 (2013).
9. Wray, N.R. *et al.* Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet* **50**, 668-681 (2018).

10. Cooper, S.A. *et al.* Multiple physical and mental health comorbidity in adults with intellectual disabilities: population-based cross-sectional analysis. *BMC Fam Pract* **16**, 110 (2015).
11. Buckley, P.F., Miller, B.J., Lehrer, D.S. & Castle, D.J. Psychiatric comorbidities and schizophrenia. *Schizophr Bull* **35**, 383-402 (2009).
12. Glessner, J.T. *et al.* Duplication of the SLIT3 locus on 5q35.1 predisposes to major depressive disorder. *PLoS One* **5**, e15463 (2010).
13. Degenhardt, F. *et al.* Association between copy number variants in 16p11.2 and major depressive disorder in a German case-control sample. *Am J Med Genet B Neuropsychiatr Genet* **159B**, 263-73 (2012).
14. O'Dushlaine, C. *et al.* Rare copy number variation in treatment-resistant major depressive disorder. *Biol Psychiatry* **76**, 536-41 (2014).
15. Rucker, J.J. *et al.* Genome-wide association analysis of copy number variation in recurrent depressive disorder. *Mol Psychiatry* **18**, 183-9 (2013).
16. Rucker, J.J. *et al.* Phenotypic Association Analyses With Copy Number Variation in Recurrent Depressive Disorder. *Biol Psychiatry* **79**, 329-36 (2016).
17. Perlis, R.H., Ruderfer, D., Hamilton, S.P. & Ernst, C. Copy number variation in subjects with major depressive disorder who attempted suicide. *PLoS One* **7**, e46315 (2012).
18. Tansey, K.E. *et al.* Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. *Pharmacogenomics J* **14**, 395-9 (2014).

19. Lorant, V. *et al.* Socioeconomic inequalities in depression: a meta-analysis. *Am J Epidemiol* **157**, 98-112 (2003).
20. Egede, L.E. Major depression in individuals with chronic medical disorders: prevalence, correlates and association with health resource utilization, lost productivity and functional disability. *Gen Hosp Psychiatry* **29**, 409-16 (2007).
21. Martin, J. *et al.* Copy number variation and neurodevelopmental problems in females and males in the general population. *bioRxiv* (2017).
22. Althubaiti, A. Information bias in health research: definition, pitfalls, and adjustment methods. *J Multidiscip Healthc* **9**, 211-7 (2016).
23. Maier, W. *et al.* Gender differences in the prevalence of depression: a survey in primary care. *J Affect Disord* **53**, 241-52 (1999).
24. Kirov, G. *et al.* The penetrance of copy number variations for schizophrenia and developmental delay. *Biol Psychiatry* **75**, 378-85 (2014).
25. Kendall, K.M. *et al.* Cognitive Performance Among Carriers of Pathogenic Copy Number Variants: Analysis of 152,000 UK Biobank Subjects. *Biol Psychiatry* **82**, 103-110 (2017).
26. Stefansson, H. *et al.* CNVs conferring risk of autism or schizophrenia affect cognition in controls. *Nature* **505**, 361-6 (2014).
27. Smith, D.J. *et al.* Prevalence and characteristics of probable major depression and bipolar disorder within UK biobank: cross-sectional study of 172,751 participants. *PLoS One* **8**, e75362 (2013).
28. Howard, D. *et al.* Genome-wide association study of depression phenotypes in UK Biobank (n = 322,580) identifies the

- enrichment of variants in excitatory synaptic pathways. *bioRxiv* (2017).
29. Spijker, J. *et al.* Duration of major depressive episodes in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). *British Journal of Psychiatry* **181**, 208-213 (2002).
 30. Murphy, S. Genotyping of 500,000 UK Biobank participants. Description of sample workflow and preparation of DNA for genotyping. Vol. 2016 (2015).
 31. Wang, K. *et al.* PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. *Genome Res* **17**, 1665-74 (2007).
 32. Purcell, S. *et al.* PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* **81**, 559-75 (2007).
 33. Davies, G. *et al.* Genome-wide association study of cognitive functions and educational attainment in UK Biobank (N=112 151). *Mol Psychiatry* **21**, 758-67 (2016).
 34. Rosseel, Y. lavaan: An R package for structural equation modeling. *Journal of Statistical Software* **48**, 1-36.
 35. Han, J. *et al.* Gender differences in CNV burden do not confound schizophrenia CNV associations. *Sci Rep* **6**, 25986 (2016).

Figure 1. A flowchart describing the study methods.

CNV Type		Self Reported Depression 24,575 affected 394,205 unaffected		Self Reported Depression and Antidepressant Prescription on Visit 1 15,748 affected, 381,681 unaffected		Hospital Discharge Diagnosis 11,395 affected 292,353 unaffected	
	Carriers	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Neurodevelopmental CNVs	1.2% (n = 4,889)	1.36 (1.22 – 1.51)	1.61×10^{-8}	1.43 (1.26 – 1.62)	5.31×10^{-8}	1.50 (1.29 – 1.73)	4.07×10^{-8}
Carrier Status of Rare (<1% CNVs)							
100KB +	48.7% (n = 203,853)	1.01 (0.98 – 1.03)	0.73	1.01 (0.98 – 1.04)	0.57	1.04 (1.00 – 1.08)	0.06
500KB+	8.9% (n = 37,309)	1.05 (1.0007 – 1.10)	0.024	1.07 (1.02 – 1.13)	0.01	1.08 (1.01 – 1.15)	0.02
1MB+	3.4% (n = 14,367)	1.02 (0.95 – 1.09)	0.59	1.03 (0.95 – 1.13)	0.45	1.03 (0.94 – 1.14)	0.52

Table 1. Association analyses for (i) neurodevelopmental CNVs, (ii) CNV burden with 3 depression phenotypes. Analyses were restricted to those of white British and Irish ancestry and excluded individuals with CNV-associated neurodevelopmental/neuropsychiatric disorders. The group of 53 neurodevelopmental CNVs were excluded from CNV burden analyses. OR – odds ratio, 95% CI – 95% confidence interval, p – uncorrected p value.

Figure 2. Analyses of individual neurodevelopmental CNVs for association with self-reported depression. Results with a p value<0.05 are marked with *, with those surviving Bonferroni correction for 53 tests being marked with **. Schizophrenia CNVs are coloured black. All the CNVs fall within the neurodevelopmental CNV group. The broken red line indicates an OR (odds ratio) of 1.

Figure 3. Further investigation of the association between neurodevelopmental CNVs and depression via social deprivation (educational attainment and physical health results are shown in Supplementary Tables 3a and 3b). Est: Estimate of effect size, SE: standard error of estimate